These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10429892)

  • 1. Growth hormone secretagogues as therapeutic agents.
    Svensson J
    Growth Horm IGF Res; 1999 Apr; 9 Suppl A():107-9. PubMed ID: 10429892
    [No Abstract]   [Full Text] [Related]  

  • 2. Growth hormone secretagogues: the clinical future.
    Micic D; Casabiell X; Gualillo O; Pombo M; Dieguez C; Casanueva FF
    Horm Res; 1999; 51 Suppl 3():29-33. PubMed ID: 10592441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone secretagogues: mechanism of action and use in aging.
    Fuh VL; Bach MA
    Growth Horm IGF Res; 1998 Feb; 8(1):13-20. PubMed ID: 10990440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New GH secretagogues and potential usefulness in thalassemia.
    Karydis I; Tolis A; Tolis G
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():857-62. PubMed ID: 10091157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally active growth hormone secretagogues.
    Patchett AA; Smith RG; Wyvratt MJ
    Pharm Biotechnol; 1998; 11():525-54. PubMed ID: 9760695
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ghrelin-related drugs: clinical perspectives].
    Shimatsu A
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():435-8. PubMed ID: 15506422
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of growth hormone secretagogues.
    Smith RG
    Endocr Rev; 2005 May; 26(3):346-60. PubMed ID: 15814848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of obese subjects with the oral growth hormone secretagogue MK-677 affects serum concentrations of several lipoproteins, but not lipoprotein(a).
    Svensson J; Jansson JO; Ottosson M; Johannsson G; Taskinen MR; Wiklund O; Bengtsson BA
    J Clin Endocrinol Metab; 1999 Jun; 84(6):2028-33. PubMed ID: 10372705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on new therapeutic options for the somatopause.
    Ceda GP; Dall'Aglio E; Morganti S; Denti L; Maggio M; Lauretani F; Andrea A; Ceresini G; Cattabiani C; Valenti G
    Acta Biomed; 2010; 81 Suppl 1():67-72. PubMed ID: 20518193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a new G-protein-linked receptor for growth hormone secretagogues.
    Pong SS; Chaung LY; Dean DC; Nargund RP; Patchett AA; Smith RG
    Mol Endocrinol; 1996 Jan; 10(1):57-61. PubMed ID: 8838145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the role of vaptans in routine clinical nephrology?
    Bichet DG
    Clin J Am Soc Nephrol; 2012 May; 7(5):700-3. PubMed ID: 22516285
    [No Abstract]   [Full Text] [Related]  

  • 13. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
    Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New growth hormone secretagogues: from physiology to the first therapeutic applications].
    Ahnfelt-Rønne I; Haahr PM
    Arch Pediatr; 1998; 5 Suppl 4():390S-396S. PubMed ID: 9853090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrelin signaling.
    Holst B; Brandt E; Bach A; Heding A; Schwartz TW
    Mol Endocrinol; 2005 Sep; 19(9):2400-11. PubMed ID: 15905359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter: Vaptans for the treatment of hyponatraemia and ascites in patients with cirrhosis.
    Karaahmet F; Coban S; Başar O; Yuksel O
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1103-4; author reply 1104. PubMed ID: 23130775
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of growth hormone (GH) secretagogues in the diagnosis of GH deficiency in humans.
    Peino R; Leal A; Garcia-Mayor RV; Cordido F; Micic D; Kopeschaar H; Dieguez C; Casanueva FF
    Growth Horm IGF Res; 1999 Apr; 9 Suppl A():101-5. PubMed ID: 10429891
    [No Abstract]   [Full Text] [Related]  

  • 18. Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.
    Svensson J; Carlsson B; Carlsson LM; Jansson JO; Bengtsson BA
    Clin Endocrinol (Oxf); 1999 Apr; 50(4):451-6. PubMed ID: 10468903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and experimental effects of growth hormone secretagogues on various organ systems.
    Svensson JA; Bengtsson B
    Horm Res; 1999; 51 Suppl 3():16-20. PubMed ID: 10592439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothalamic targets for growth hormone secretagogues.
    Robinson IC
    Acta Paediatr Suppl; 1997 Nov; 423():88-91. PubMed ID: 9401551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.